Cargando…

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B

The most relevant endpoint in therapeutic HIV vaccination is the assessment of time to viral rebound or duration of sustained control of low-level viremia upon cART treatment cessation. Structured treatment interruptions (STI) are however not without risk to the patient and reliable predictors of vi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosás-Umbert, Miriam, Mothe, Beatriz, Noguera-Julian, Marc, Bellido, Rocío, Puertas, Maria C., Carrillo, Jorge, Rodriguez, C., Perez-Alvarez, Núria, Cobarsí, Patricia, Gomez, Carmen E., Esteban, Mariano, Jímenez, Jose Luis, García, Felipe, Blanco, Julià, Martinez-Picado, Javier, Paredes, Roger, Brander, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617163/ https://www.ncbi.nlm.nih.gov/pubmed/28953921 http://dx.doi.org/10.1371/journal.pone.0184929

Ejemplares similares

Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers
por: Rosás-Umbert, Miriam, et al.
Publicado: (2019)

HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design
por: Bayón-Gil, Ángel, et al.
Publicado: (2020)

Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)
por: Mothe, Beatriz, et al.
Publicado: (2019)

Corrigendum to ‘Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)’ EClinicalMedicine 11 (2019) 65–80
por: Mothe, Beatriz, et al.
Publicado: (2020)

Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome
por: Oriol-Tordera, Bruna, et al.
Publicado: (2022)

Modulation of antibody secreting cells and neutralizing Ab activity in HIV infected individuals undergoing structured treatment interruptions
por: Llano, A, et al.
Publicado: (2012)

The Immunological and Virological Consequences of Planned Treatment Interruptions in Children with HIV Infection
por: Klein, Nigel, et al.
Publicado: (2013)

Virological, Immune and Host genetics Markers in the Control of HIV Infection
por: Mothe, Beatriz, et al.
Publicado: (2009)

Virological Outcome Measures During Analytical Treatment Interruptions in Chronic HIV-1-Infected Patients
por: Fehér, Csaba, et al.
Publicado: (2019)

Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B
por: Couto, Elvira, et al.
Publicado: (2019)

Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions
por: Llano, Anuska, et al.
Publicado: (2013)

Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study
por: Sanchez, Jorge, et al.
Publicado: (2020)

Long‐term clinical, virological and immunological outcomes following planned treatment interruption in HIV‐infected children
por: Freguja, R, et al.
Publicado: (2020)

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART
por: Gómez, Carmen Elena, et al.
Publicado: (2015)

Virology and Immunology of Bats
por: Schountz, Tony
Publicado: (2013)

General Virology
por: Garcia-Blanco, Mariano A.
Publicado: (1979)

Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes
por: Sued, Omar, et al.
Publicado: (2015)

Disruption of the HLA-E/NKG2X axis is associated with uncontrolled HIV infections
por: Romero-Martín, Luis, et al.
Publicado: (2022)

Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART
por: Puertas, Maria C., et al.
Publicado: (2016)

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults
por: Green, C, et al.
Publicado: (2023)

Hepatitis B and Pregnancy: Virologic and Immunologic Characteristics
por: Joshi, Shivali S., et al.
Publicado: (2020)

Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy In Vitro
por: Olvera, Alex, et al.
Publicado: (2018)

In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial
por: Rosás-Umbert, Miriam, et al.
Publicado: (2020)

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
por: Hancock, Gemma, et al.
Publicado: (2017)

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
por: Mothe, Beatriz, et al.
Publicado: (2020)

The infectious synapse formed between mature dendritic cells and CD4(+) T cells is independent of the presence of the HIV-1 envelope glycoprotein
por: Rodriguez-Plata, Maria T, et al.
Publicado: (2013)

Vaccination with an HIV T-Cell Immunogen (HTI) Using DNA Primes Followed by a ChAdOx1-MVA Boost Is Immunogenic in Gut Microbiota-Depleted Mice despite Low IL-22 Serum Levels
por: Elizalde-Torrent, Aleix, et al.
Publicado: (2023)

Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
por: Meseda, Clement A., et al.
Publicado: (2016)

The prognosis of patients with dissociated virological and immunological responses to HAART
por: Jevtovic, DJ, et al.
Publicado: (2010)

Immunological and virological aspects of HIV cell-to-cell transfer
por: Schwartz, Olivier
Publicado: (2009)

Virology and Immunology Researchers Evolve with the Viruses We Study
por: Russell, Rodney S.
Publicado: (2020)

Insights into the virologic and immunologic features of SARS-COV-2
por: Polat, Ceylan, et al.
Publicado: (2021)

Small steps forward for HIV vaccine development
por: Mothe, Beatriz, et al.
Publicado: (2020)

Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2023)

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals
por: Kawana-Tachikawa, Ai, et al.
Publicado: (2014)

The Effect of HIV Treatment Interruption on Subsequent Immunological Response
por: Thomadakis, Christos, et al.
Publicado: (2023)

Predictive Immunological, Virological, and Routine Laboratory Markers for Critical COVID-19 on Admission
por: García-Gasalla, Mercedes, et al.
Publicado: (2021)

The 90 MVA transformer
Publicado: (1974)

Immunological and Virological Mechanisms of Vaccine-Mediated Protection Against SIV and HIV
por: Roederer, Mario, et al.
Publicado: (2013)

The Genome-wide Methylation Profile of CD4(+) T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression
por: Moron-Lopez, Sara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9vh9qktbics45csn2ovuqs3d9r